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Efficacy of a Cell Extract from Actinobacillus (Haemophilus)
pleuropneumoniae Serotype 1 against Disease in Swinet
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We partially characterized a cell extract (CE) from Actinobacillus pleuropneumoniae serotype 1 and used the
CE to test the efficacy of secreted proteins against disease. Secreted products from 4-h culture supernatants
were precipitated with 20% polyethylene glycol. Analysis of the CE indicated the presence of protein,
endotoxin, and carbohydrate. Hemolytic activity to bovine erythrocytes and cytotoxic activity to porcine
mononuclear leukocytes was also demonstrated. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
analysis of the CE from a 4-h culture showed a major band at 110 kilodaltons (kDa), while a CE of a 26-h
culture indicated the presence of a number of additional proteins, including the 110-kDa protein. The 110-kDa
protein was also identified as a glycoprotein by periodic acid-Schiff and silver staining. A single band
precipitated against convalescent-phase pig antiserum when the polyethylene glycol precipitate was used in an
Ouchterlony plate. Vaccination with CE conferred greater protection against challenge with the homologous
serotype than either a commercial bacterin or an outer membrane protein vaccine. Hemolysin-neutralizing
titers were higher both pre- and postchallenge in the group vaccinated with the CE compared with in all other
groups. We believe that this demonstrates the importance of secreted factors in protection against disease and
suggests that the 110-kDa protein is an important immunogen.
Actinobacillus (Haemophilus) pleuropneumoniae is a
gram-negative, pleomorphic rod that requires V factor (P-
nicotinamide dinucleotide) but not X factor (hemin) or serum
for growth (8). A. pleuropneumoniae causes a highly conta-
gious disease characterized by pleuropneumonia in pigs of
all ages but primarily affects growing pigs 2 to 6 months old.
The disease occurs worldwide; at least 10 serotypes have
been identified, and it appears to be increasing in prevalence
because of intensified production practices (19, 38, 40).
Schultz et al. (39) reported that the incidence of A. pleuro-
pneumoniae-associated pleuropneumonia has increased
markedly since 1976, so that 68.8% of the Iowa herds tested
were seropositive for A. pleuropneumoniae. The financial
losses due to this disease have been estimated at millions of
dollars annually (R. A. Shultz, Proc. George Young Conf.,
p. 89-92). Sebunya and Saunders (40) suggested that an
inadequate understanding of the pathogenesis of A. pleuro-
pneumoniae infections results in failure to control the dis-
ease.
Serotypes 1, 5, and 7 are the predominant serotypes
isolated from A. pleuropneumoniae outbreaks in the United
States. One approach to controlling infections has been
vaccination with whole-cell bacterins (17, 23, 35); however,
results have been less than optimal. Current vaccines are
composed of a combination of chemically inactivated A.
pleuropneumoniae adjuvant-treated serotypes (12, 29) which
may confer immunity to the bacterial cells but not necessar-
ily to secreted products that are involved in pathogenesis.
Identification of specific virulence factors and their role in
stimulating protective immunity has been the focus of cur-
rent research (17, 18, 22, 25, 26, 31, 36, 40, 41; J. Ma, J.
Todd, and T. Inzana, Abstr. Annu. Meet. Am. Soc. Micro-
biol. 1989, B180, p. 60). Virulence factors that have been
* Corresponding author.
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identified for A. pleuropneumoniae include hemolysins, en-
dotoxins, exotoxins, capsular polysaccharides, lipopolysac-
charides, permeability factor, and outer membrane proteins,
including iron-regulated proteins (6, 7, 10-15, 18, 20, 22,
25-29, 31, 36, 41). Capsular polysaccharides are serotype
specific and poorly immunogenic (18). Protection with par-
tially purified outer membrane proteins (OMPs) and lipo-
polysaccharides was comparable with that of current com-
mercial products (10-12, 33), and partial protection was
reported for a capsular polymer (17).
In this paper, we report the partial characterization of a
cell extract (CE) with one major protein band from A.
pleuropneumoniae serotype 1. We also show the efficacy of
this extract in protecting swine from A. pleuropneumoniae-
induced disease.
MATERIALS AND METHODS
Bacterial strains and stock cultures. The strains used in this
study were field isolates (Table 1). Isolates were serotyped at
the Iowa State University Veterinary Diagnostic Labora-
tory, Ames. All stocks were maintained as cultures frozen at
-70°C in brain heart infusion broth (BHI) (Difco Laborato-
ries, Detroit, Mich.) containing 40% glycerol and 1% NAD
(Sigma Chemical Co., St. Louis, Mo.; final concentration, 20
jig/ml) added after sterilization of the medium. Inoculum
flasks were prepared by adding 0.1 ml of the frozen stock to
fresh BHI supplemented with 1% NAD. Frozen stocks were
checked for purity at the time of inoculation by using 5%
bovine blood agar plates containing 1% NAD.
Culture conditions. Inocula were incubated overnight at
37°C and 200 rpm on a New Brunswick G25 reciprocal
shaker. A 1% (vol/vol) inoculum was transferred to new
medium, and the production flask was incubated under
identical conditions for 4 h to an A600 of 1.0 (approximately
108 CFU/ml).
Extract preparation. Production cultures from serotype 1
were centrifuged at 14,000 x g for 20 min at 4°C. Precipitate
was obtained from pooled supernatant fluids by a modifica-
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TABLE 1. List of groups
Group no. No. of pigs Vaccine Strain Serotype
Vaccine trial 1
1 6 CE GA88 la
2 6 OMPs (serotypes GA88 1
1, 5, and 7)
5FWC 5a
7MPC 7
3 3 Emulsibac H.P. b 1, 5, 7
4 3 PBS control
Vaccine trial 2
1 5 CE GA88 la
2 3 PBS control
a From our collection.
b_, Information unavailable.
tion of the method of Bhadki et al. (2). Briefly, 3% glycerol
and 20% polyethylene glycol (PEG) (Sigma) were added to
the supernatant and stirred overnight at 4°C (2). The precip-
itate was collected by centrifugation (14,000 x g for 20 min)
and dissolved in 10 mM Tris-10 mM CaCl2-0.15 M NaCl
buffer, pH 6.8. The extract was dialyzed against 400 volumes
of the same buffer overnight and then filtered through a
0.22-,um-pore-size cellulose acetate filter (Nalgene Labware
Div., Nalge/Sybron Corp., Rochester, N.Y.). The resulting
CE was stored at 4°C until it was incorporated with adjuvant.
CE from a 26-h culture was also prepared as described above
for comparison between log-phase and stationary-phase cul-
tures.
Vaccine preparation. The 4-h sterile CE was mixed with
20% Emulsigen adjuvant (provided by MVP Laboratories;
final concentration, 100 ,ug of total protein per 2.0-ml dose).
The preparation was stored at 4°C. Negative control material
was prepared by using phosphate-buffered saline (PBS)
mixed with 20% Emulsigen. A commercial product, Emul-
sibac H.P., was used as a positive vaccine control.
Preparation of OMPs. OMPs were enriched by a modifi-
cation of the method of Carlone et al. (4) with sodium
N-lauroylsarcosinate (sarcosyl; Sigma). Serotype 1, 5, and 7
cultures were prepared as described above. Briefly, 10 ml of
culture was centrifuged at 10,000 x g, and the pellet was
suspended in 1.0 ml of 10 mM HEPES (N-2-hydroxyeth-
ylpiperazine-N'-2-ethanesulfonic acid), pH 7.4, and soni-
cated (six 10-s bursts). The sonic extract was centrifuged at
15,000 x g for 2 min in an Eppendorf Microfuge at 4°C, the
pellet was discarded, and the supernatant was transferred to
a new Microfuge tube and centrifuged at 15,000 x g for 30
min at 4°C. The supernatant was discarded, and the pellet
was suspended in 0.2 ml of HEPES. Cytoplasmic mem-
branes were solubilized after the addition of an equal volume
of 2% sarcosyl in HEPES. The preparation was incubated at
room temperature for 30 min with gentle shaking on a Vortex
Genie 2 (Scientific Industries, Bohemia, N.Y.). The prepa-
ration was centrifuged at 15,000 x g for 30 min at 4°C, and
the supernatant was discarded. The sarcosyl-insoluble OMP
pellet was washed once without suspension in HEPES,
centrifuged for 5 min at 15,000 x g, suspended in 100 p.l of
HEPES, and frozen at -20°C. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis
was performed as described below.
Before being used, the protein content was determined as
described below and adjusted to 40 p.g of protein per 0.5 ml
of PBS. The three serotype OMPs were combined and mixed
with 20% Emulsigen (120 p.g of total protein per 2.0-ml
dose).
Test animals. Specific-pathogen-free pigs (4 to 6 weeks
old) were housed in containment facilities according to
Institutional Animal Care and Use Committee guidelines. All
test animals were seronegative to A. pleuropneumoniae as
measured by an enzyme-linked immunosorbent assay
(ELISA) as described below.
ELISA. Polystyrene U-bottom microtiter plates (Dyna-
tech, Chantilly, Va.) were coated with 10 Rxg of poly-L-lysine(Sigma) per ml in PBS and incubated for 1 h at 37°C. The
poly-L-lysine was removed, and 50 ,ul of washed A. pleuro-
pneumoniae serotype 1 (2 x 106 CFU in PBS; culture
conditions were as described above) was added per well.
The plates were centrifuged at 2,000 x g for 5 min, and 150
,ul of blocking buffer (10 mM glycine, 1% bovine serum
albumin in PBS) was added to each well without removal of
the bacteria. The plates were incubated at room temperature
for 30 min, washed three times with PBS, and air dried.
Plates were stored for up to 1 year at room temperature.
Before being used, plates were rehydrated with 50 ,u1 of
diluent buffer (0.5% bovine serum albumin, 0.05% Tween 20
in PBS) per well. Serial twofold dilutions of the test serum
were done with diluent buffer in a separate microtiter plate,
and 25 ,ul was transferred to the coated plate. All samples
were tested in duplicate. The plates were incubated at 37°C
for 1 h and washed three times with PBS plus 0.05% Tween
20 in a Dynatech washer. A 1:1,000 dilution of phosphatase-
labeled goat anti-swine immunoglobulin G (gamma specific)
(Kirkegaard and Perry Laboratories, Gaithersburg, Md.) in
diluent buffer was prepared, and 50 ,ul was added to each
well. The plates were incubated for 1 h at 37°C and washed
three times with PBS-0.05% Tween 20. Phosphatase sub-
strate tablets (Sigma) were dissolved in diethanolamine
buffer (9.7% diethanolamine, 0.02% sodium azide, 0.01%
magnesium chloride in water, pH 9.8), and 100 ,1u was added
to each well. The plates were incubated for 30 min at room
temperature. A410s of the plates were determined in a
Dynatech MR700 plate reader. PBS was used as a negative
control.
Challenge model. Bacteria were prepared as described
above except that the cells were washed once with PBS
before dilution. Cells were diluted to a final A6. of 0.05 to
0.07 (approximately 4 x 107 CFU) and then diluted 1:10. Pigs
were individually restrained in a vertical position without
anesthesia and challenged intranasally with 5 ml of PBS
containing one ml of the 1:10 dilution (approximately 4 x 106
cells). A vacuum pump with a positive pressure of approxi-
mately 5 lb/in2 and a nasal cannula (Nobl Labs, Sioux
Center, Iowa) connected to Tygon tubing were used for
intranasal instillation. A 5-ml PBS wash followed the bacte-
rial suspension to clear the tubing and to ensure inspiration
of maximum challenge volume.
Vaccine trial 1. Eighteen test animals were randomly
distributed into two groups of six pigs (groups 1 and 2) and
two groups of three pigs (groups 3 and 4) (Table 1). All pigs
were vaccinated on days 0 and 21. Group 1 received 2 ml of
the CE vaccine as described above, group 2 received 2 ml of
the combination OMP preparation, group 3 received 2 ml of
the commercial vaccine, and group 4 received 2 ml of the
adjuvant-treated PBS control. All vaccinations were given
by intramuscular injection into the cervical musculature. All
pigs were challenged as described above on day 35. The pigs
were weighed and bled weekly. In addition, rectal tempera-
tures and clinical observations were made daily postchal-
lenge. Clinical signs included increased respiration rate,
coughing, sneezing, diarrhea, vomition, nasal exudate, and
depression. Scores ranged from 0 to 5, with 0 being normal
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FIG. 1. Lung diagram indicating the percentage of the total lung
volume assigned to each lobe. Slash marks indicate areas cultured
for bacteria at necropsy.
and 5 being most severe. Pigs were euthanatized and
necropsied on day 39, and lung scores were recorded as a
percentage per lobe. The lung score was calculated by
multiplying the estimated percentage of lung affected by the
values assigned in Fig. 1 followed by the addition of all
values. In addition, affected lungs were cultured for the
presence of A. pleuropneumoniae on 5% blood agar plates
containing 1% NAD. Cultures were taken from a central area
of the right caudal lobe in normal-appearing lungs. Pigs that
died before day 39 were weighed and necropsied immedi-
ately after death.
Vaccine trial 2. A second trial was conducted to confirm
the efficacy of the CE as described above, except that eight
pigs were randomly divided into two groups; group 1 had five
pigs, and group 2 had three pigs. Group 1 received 2 ml of the
CE, and group 2 received 2 ml of the PBS control. All
surviving pigs were euthanatized on day 44.
Biological assays. Hemolytic activity of the CE was deter-
mined by using an in-well lysis procedure in 96-well micro-
titer plates. Test samples were diluted twofold in 10 mM Tris
chloride-10 mM CaCl2-0.15 M NaCl, pH 7.4 (TCN buffer).
An equal volume of a 2% suspension of washed bovine
erythrocytes was added to each well, and the plate was
incubated for 2 h at 37°C. In all cases, duplicate samples
were run. The plate was centrifuged at 1,500 x g, and
one-half the volume was carefully aspirated by using a
Titertek multichannel Pipetman (Flow Laboratories Inc.,
McLean, Va.) and transferred to a new 96-well microtiter
plate. The A410 of the plate was determined on a Dynatech
MR 700 ELISA reader. Buffer was the negative control, and
distilled water was used for complete lysis of the bovine
erythrocytes for the positive control. The titer was deter-
mined to be the reciprocal of the last dilution giving an A410
above the value for 5% of the positive control. Hemolysin-
neutralizing titers were determined by twofold dilution in
TCN buffer followed by the addition of an equal volume of
hemolysin adjusted to a titer of 50 to 100. A hemolysin
control well was TCN plus diluted hemolysin. Neutralization
titers were determined as the reciprocal of the highest
dilution neutralizing 50% of the hemolysin control.
A phenol-sulfuric acid carbohydrate analysis was done by
the method of Dubois et al. (9). Endotoxin was determined
by using the quantitative chromogenic Limulus amebocyte
lysate kit from Whittaker M.A. Bioproducts (Walkersville,
Md.) by following the instructions of the manufacturer.
Cytotoxin titers to leukocytes were determined as previ-
ously described (21) by using the lactate dehydrogenase
assay. Porcine peripheral blood mononuclear cells were
used as the target cells.
Ouchterlony assays. Double diffusion assays were carried
out by the method of Ouchterlony (30) with 1.0% agarose
(Bio-Rad Laboratories, Richmond, Calif.) in PBS (pH 7.0).
Convalescent-phase sera from serotype 1 was used from
control animals who survived the challenge. After samples
were added, the agarose plates were incubated at 4°C in a
humidity chamber for 24 h. After precipitation, the gel was
copiously washed in PBS to remove unbound proteins and
dried in a gel dryer (Bio-Rad). The dried gel was stained with
Coomassie blue as described below.
Electrophoresis. SDS-PAGE with 0.1% SDS was done in
the discontinuous gel system of Laemmli (24) in a Bio-Rad
Mini-Protean II system. Protein in samples was dissociated
by the addition of double-strength sample buffer (Sigma
Technical Note no. MWS-877L) containing 10% SDS (final
concentration) followed by heating at 100°C for 3 min.
Proteins were reduced by the inclusion of mercaptoethenol
in the sample buffer. Approximately 10 ,ug of protein per
sample was added per well. Low- and high-molecular-weight
standards were prepared by the method described in Sigma
Technical Note no. MWS-877L. Electrophoresis was carried
out at constant voltage (70 V) for approximately 2.5 h, until
the bromophenol blue marker had reached a position 2 mm
from the bottom of the gel. Gels were fixed and stained with
a solution of 0.1% Coomassie brilliant blue R250, 10% acetic
acid, and 45% methanol and were destained with 10%
methanol in 10% acetic acid. Additional gels were stained for
the presence of carbohydrate by using a periodic acid-Schiff
stain. Gels were incubated for 1 h at room temperature in
7.5% acetic acid. A 1:5 dilution of periodic acid Accustain
(final concentration, 0.2%; Sigma) replaced the acetic acid,
and the gel was refrigerated at 4°C for 45 min. Without being
rinsed, the gels were placed into undiluted Schiff reagent
Accustain (Sigma) and refrigerated for 45 min. Gels were
destained in two to three changes of 10% acetic acid at room
temperature. Gels were also stained with silver (Bio-Rad)
according to manufacturer directions.
Determination of protein. Total protein was determined by
the method of Bradford (3) with bovine serum albumin as the
standard.
Statistics. Lung score data were analyzed by using a
one-way analysis of variance model.
RESULTS
Characterization of the CE. We have been able to identify
the presence of hemolytic and cytotoxic activities in addition
to the presence of carbohydrate and endotoxin in the CE
(Table 2). These values represent the activities present
before the addition of Emulsigen. Approximately 450 ,ug of
protein per ml was obtained in the final product. The
hemolytic activity was destroyed after heating for 15 min at
100°C (P. J. Fedorka-Cray, G. A. Anderson, M. J. Huether,
and D. L. Stine, Abstr. Annu. Meet. Res. Work. Anim. Dis.
1987, 151, p. 4), whereas the cytotoxic activity was unaf-
fected. The hemolytic activity was stable at 4°C for at least
6 months. SDS-PAGE analysis indicated that the major
protein band in the CE was of approximately 110 kilodaltons
(kDa) (Fig. 2). The 110-kDa band was identified as a glyco-
protein (Fig. 3 and 4) after periodic acid-Schiff and silver
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TABLE 2. Properties of the CE used in trials 1 and 2 (CE-1 and
-2), the OMP preparation used in trial 1, and the medium control
before combination with the adjuvant used in both trials
Hemolytic Carbo- EPreparation activity hydrate Endotoxln Cytotox-
(dilution) (mg/mi) (U/mi) icity (%)
PBS control 0 0.5 3.1 x 101 0
CE-1 1,024 5.4 4.8 x 106 17.5
CE-2 2,048 6.4 3.3 x 106 28.5
OMP NDa 1.2 2.0 x 106 ND
BHI-PEG 0 7.1 7.6 x 101 5.0
a ND, Not done.
staining. Additional proteins in the CE are identified in Fig.
4. The number of proteins obtained from the supernatant
increased dramatically (Fig. 5) as culture age increased.
Hemolytic activity of the 26-h culture was .1,024. How-
ever, this activity was stable for less than 1 week at 4°C.
Ouchterlony analysis (Fig. 6) indicated one precipitin band
between the convalescent-phase serum and the 4-h CE.
Anti-serotype 1 hemolysin titers are indicated in Table 3.
Antibody titers for the CE and bacterin groups were appar-
ent by day 35. Neutralizing titers were significantly higher
for the CE group postchallenge than for the other groups.
Hemolysin neutralizing titers were not done for trial 2.
A mild to moderate (40.1 to 41.1°C) febrile response was
observed after vaccination with the CE preparation for both
trials; however, these values were similar to those seen after
vaccination with the commercial product (41.2°C) or with the
OMP preparation (41.0°C). In addition, pigs from all groups,
excluding the PBS controls, exhibited mild depression for
approximately 18 h postvaccination. All pigs appeared clin-
ically normal and had rectal temperatures within the normal
range 24 h postvaccination.
Characterization of the OMP preparations. Both carbohy-
drate and endotoxin (Table 2) were present in the OMP
preparations, indicating that only partial purification was
1 2
205K
116K _-
9741K -
66K
45K
29K _%,
FIG. 3. Periodic acid-Schiff stain of 4-h CE. Lanes: 1, molecular
mass standards (see legend to Fig. 2) (unstained); 2, 4-h CE
(110-kDa band is indicated).
achieved. Hemolytic and cytotoxic activities were not deter-
mined. Approximately 250 ,ug of OMP protein was obtained
from 10 ml of culture. SDS-PAGE analysis of the prepara-
tions is shown in Fig. 7.
Clinical evaluations. Pigs vaccinated with CE exhibited
lower postchallenge temperatures (lower by 0.5 to 0.9°C)
than all other vaccinated and control pigs for both clinical
trials. Clinical scores (Table 4) were also lower in the CE
groups. Pigs vaccinated with CE remained normal or showed
only mild clinical signs, while other groups were mildly to
severely affected by the challenge.
A. pleuropneumoniae was recovered from a majority of
the vaccinated pigs (70% of CE vaccinates and 60% of the
OMP vaccinates) and from all of the control pigs for both
3
.4-
FIG. 2. SDS-PAGE of the CE. Lanes: 1, molecular mass stan-
dards (myosin, 205 kDa [K]; 3-galactosidase, 116 kDa; phosphory-
lase b, 97.4 kDa; bovine albumin, 66 kDa; egg albumin, 45 kDa;
carbonic anhydrase, 29 kDa); 2, 4-h CE (arrow indicates a major
band at approximately 110 kDa); 3, BHI-PEG control.
FIG. 4. Silver stain of 4-h CE. Lanes: 1, molecular mass stan-
dards (bovine albumin, 66 kDa; egg albumin, 45 kDa; glyceralde-
hyde-3-phosphate dehydrogenase, 36 kDa; carbonic anhydrase, 29
kDa; trypsinogen, 24 kDa; trypsin inhibitor, 20.1 kDa; lactalbumin,
14.2 kDa); 2, 4-h CE (110-kDa band is indicated; other proteins
unstained by Coomassie blue are visible).
1
-110
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FIG. 5. Comparison of 4- and 26-h CEs. Lanes: 1, molecular
mass standards (as described in the legend to Fig. 4); 2, 4-h CE; 3,
26-h CE; 4, BHI-PEG control. Gel was stained with Coomassie
blue; arrow indicates 110-kDa protein.
trials. All pigs seroconverted to the homologous strain as
demonstrated by ELISA titers (data not shown). Lung
scores (Table 5) showed a positive association with clinical
scores. CE vaccinates had a significantly lower percentage
(P < 0.05) of lung affected in both trials than the control
group. No significant difference was detected among the
other treatment groups and the CE group in trial 1. Lung
lesions were confined to the caudal lobes in a majority of the
pigs, with some involvement observed in the middle and
cranial lobes. In trial 1, nearly 100% of the lungs in the
control group were affected, whereas less involvement was
observed in trial 2 control pigs (31%). Lung lesions typical of
those from control pigs are illustrated in Fig. 8.
TABLE 3. Anti-serotype 1 hemolysin titers
Group Hemolysin titer on day:
(vaccine) 35 40
1 (CE) s0a 93a
2 (OMP) 0 12
3 (bacterin) 35a 16
4 (control) 0 b
a p < 0.05 compared with all other groups.
b_, All control pigs died.
ties. It should be noted that a considerable portion of the
carbohydrate activity may be due to precipitation of the
medium, as seen in Table 2 (BHI-PEG yielded 7.1 mg of
carbohydrate per ml), and 10 to 14% of the carbohydrate is
utilized during growth. Additionally, a portion of the free
carbohydrate may be attributed to precipitation of capsular
material that is released from the cells during growth and
processing. The capsule may not play a major role in
protection, since capsule alone is a poor immunogen (18) and
acapsular mutants appear to be as virulent as the parent
strain (17). This theory may also be extended to include
endotoxin, on the basis of previous work by Fenwick and
co-workers (10-12). However, capsule, endotoxin, and
OMPs may be collectively involved in protection. We rec-
ognize that carbohydrate is also associated with the 110-kDa
protein. However, until purification of this protein is
achieved, we can only speculate as to its nature and role.
It has been suggested that protein secretions may be
important virulence factors for other organisms (5). On the
basis of this work with a CE containing a major 110-kDa
protein band and the report of Devenish et al. (7), we believe
that our 110-kDa protein band is the accepted hemolysin
reported by Frey and Nicolet (14) and that it may be an
important immunogen for A. pleuropneumoniae. Further-
more, the CE shown in Fig. 2 and 5 has stable hemolytic
1 2 3 4
DISCUSSION
The vaccine evaluated in these studies was a CE, unlike
the OMP preparation and current commercial bacterins. The
CE vaccine was composed of protein, carbohydrate, and
endotoxin, and it exhibited hemolytic and cytotoxic proper-
205K_=
116K-
97.4K _
66K so
45K
U
29K _0
._
CFE
FIG. 6. Ouchterlony assay stained with Coomassie blue. C,
Convalescent-phase serum from a pig infected with A. pleuropneu-
moniae serotype 1; B, BHI-PEG control; CFE, 4-h CE. A total of 80
pd was added to each well; the CE preparation was undiluted.
FIG. 7. SDS-PAGE gel of the OMPs. Lanes: 1, molecular mass
standards (as described in the legend to Fig. 2); 2, A. pleuropneu-
moniae serotype 1; 3, A. pleuropneumoniae serotype 5; 4, A.
pleuropneumoniae serotype 7.
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TABLE 4. Average clinical score per group after intranasal
challenge on day 35 for trial 1 and on day 43 for trial 2
Avg clinical score per groupa after vaccination with
Trial (group no.):
and
day CE OMP Commercial Control
(1) (2) vaccine (3) (4)
Trial 1
35b 0.8 1.5 2.0 6.5c
36 0.4 2.5 2.0 8.0
37 0.2 1.3 1.7 7.0
38 0.8 1.5 2.7 e
39 0 1.5 0.7
40 0 1.0 0.7
Trial 2
35b 0.5 2.0
36 0 0.5
37 0 2.0
38 0.3 4.5
39 0 3.5
40 0 3.5
41 0.3 4.5
42 1.0 3.0
43 0.3 2.5
a Average clinical score = (all scores for each clinical sign per group)/(total
number of surviving pigs per group).
b Six hours postchallenge.
c One pig died at 5.5 h postchallenge.
d One additional pig died.
e-, Remaining control pigs died.
activity (hemolysin titer remained at 1,024 for 1 year after
preparation), unlike the activity generated from a 26-h cul-
ture. This difference in activity may be due in part to the
culture age and purity of the preparation, as other macro-
molecules may serve to stabilize the hemolytic activity.
Kamp and VanLeengoed (20) also suggest that differences in
activity may be due to the different media used for genera-
tion of the hemolysin. However, SDS-PAGE analysis of the
CE strongly implicated the hemolysin as the major secreted
protein (Fig. 2 through 5), and Ma et al. (Abstr. Annu. Meet.
Am. Soc. Microbiol. 1989) suggested that the hemolysin
from serotype 5 was a critical component for virulence, as
did Devenish et al. (7).
Devenish et al. (7) and Frey and co-workers (13-15)
identified two hemolysins, a 104- to 105-kDa protein and a
27-kDa protein, respectively, that are found in all serotypes
of A. pleuropneumoniae. Kamp and VanLeengoed (20)
identified a hemolysin in serotypes 1, 5, 9, 10, and 11 and a
cytotoxin in all serotypes except 6. Antisera to the 104-kDa
protein neutralized the activity to hemolysin from all sero-
types (7), while cross-neutralization of cytotoxin between all
serotypes was not demonstrated (20). Convalescent-phase
sera from the CE and bacterin groups neutralized the hemo-
TABLE 5. Average percentage of lung showing pleuropneumonia
per group for trials 1 and 2
Percentage of lung showing pleuropneumonia (mean + SD) for:
Trial CE OMP Commercial
vaccinates vaccinates vaccinates Controls
1 9.0 + 9.1a 19.2 ± 12.9 15.0 + 8.4 70.0 ± 6.8
2 oa NDb ND 30.8 + 18.1
a P < 0.05 compared with control group.
b ND, Not done.
FIG. 8. Dorsal view showing A. pleuropneumoniae lesions af-
fecting approximately 50% of the total lung. Arrow indicates in-
volvement in caudal lobe.
lytic activity from A. pleuropneumoniae serotype 1, as
shown in Table 3. These data support the observations of
other investigators and suggest either that the OMP prepa-
ration did not have hemolysin present or that an immune
response to a possible hemolysin in the preparation was not
neutralizing.
Ouchterlony analysis indicated that few other proteins are
excreted and recognized in the precipitation. This further
suggests that the presence of the 110-kDa protein may be
significant for protection, as we would have expected addi-
tional precipitin bands if other proteins were present in
significant amounts in the CE.
SDS-PAGE analysis of the OMP preparations from sero-
types 1, 5, and 7 were consistent with those reported by
Rapp et al. (32) and Rycroft and Taylor (37). We have
confirmed previous findings (33) that A. pleuropneumoniae
OMP provided some protection against pleuropneumonia in
pigs; however, it appeared to be less effective than the CE.
However, since protection of the pigs vaccinated with OMP
was greater than that of the control group, a combination of
excreted proteins and OMPs may provide even greater
protection than with CE or OMP alone. The postvaccination
febrile responses in all our groups may have been due to the
presence of endotoxin.
The challenge inoculation resulted in elevated tempera-
tures and clinical signs in the control groups during both
trials. The CE vaccinates showed fewer signs of disease than
any of the other groups for all parameters evaluated. Two
aspects of CE-vaccinated pigs are most striking: the de-
creased severity of clinical signs and the percentage of lung
affected by lesions. It should be noted that all pigs exhibited
some clinical signs and elevated temperatures, suggesting
the presence of an A. pleuropneumoniae infection. Not all
CE-vaccinated pigs exhibited lung damage; however, A.
pleuropneumoniae was recovered from 83% of the CE-
vaccinated lungs in trial 1 and from 50% of them in trial 2,
while 100% recovery was observed for the controls of both
trials. Thus, colonization may not have occurred in some
lungs, or bacteria may have been cleared from the respira-
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tory tracts of vaccinated pigs. All animals responded immu-
nologically as demonstrated by elevated ELISA antibody
titers. Further work, including bacterial culturing of the
blood and/or spleen, is needed to confirm clearance of A.
pleuropneumoniae, particularly since we have been able to
isolate A. pleuropneumoniae from these tissues at necropsy
from severely infected pigs (unpublished observations).
In conclusion, A. pleuropneumoniae is an important res-
piratory pathogen, and it appears that vaccination with a CE
can provide significant protection. However, until each
component of the CE is purified and tested, definitive
identification of a single primary protective immunogen
cannot be determined.
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